|Program||Target Indication||Region||Research||Preclinical||Phase I||Phase II||Phase III||Filing||Approval||Out-licensed|
|Chugai Pharmaceutical Co., Ltd.|
|Solid tumor||USA||FUJIFILM Corporation|
|Hematologic cancer||Developing in-house|
|Solid tumor||FUJIFILM Corporation|
PPMX-T001 targets glypican 3 (GPC3), which is expressed on the surface of cancer cells. A transcriptome analysis performed by LSBM at the University of Tokyo has revealed that GPC3 is highly expressed in liver cancer. GPC3 is an approximately 60-kDa glycoprotein associated with the cell membrane via a glycosylphosphatidylinositol anchor. Currently, PPMX-T001 is under evaluation for treating liver cancer in a clinical trial sponsored by Chugai Pharmaceutical Co., Ltd.
PPMX-T002 targets cadherin 3 (CDH3) that is expressed on the surface of cancer cells. A transcriptome analysis performed by LSBM at the University of Tokyo has revealed that CDH3 is highly expressed in various cancers but is poorly expressed in major healthy organs. CDH3 consists of five extracellular cadherin domains and one transmembrane domain, and is considered to function as an intercellular adhesion protein.
PPMX-T002 is a chimeric antibody against CDH3 and was developed by modifying an antibody generated using the hybridoma method. PPMX-002 has been licensed to Fujifilm Corporation; it was developed as a radioisotope conjugated antibody therapeutics. Currently, an ongoing clinical trial, sponsored by Fujifilm Corporation, is evaluating the efficacy of PPMX-002 against solid tumors.
PPMX-T003 targets transferrin receptor (TfR) that is expressed on the cell membrane and regulates cellular iron uptake. The cellular iron uptake is essential for cell survival and proliferation. It is widely known that TfR is highly expressed in many cancer cells. The inhibition of iron uptake depletes its levels within cells, leading to cell death. We have developed a fully human antibody, PPMX-T003, which shows extremely potent inhibitory activity against iron uptake, using the phage display method. We are planning clinical trials to evaluate this antibody for several indications.
PPMX-T004 targets CDH3. It is generated using the hybridoma method and has a high potency of internalization. It has been developed as an ADC and is licensed to Fujifilm Corporation.